EHAB

Enhabit Inc

Add to Watchlist

Advanced Chart

8.040

-0.11(-1.350%)1D

Line

Candle

YTD

High

8.100

Open

7.940

VWAP

8.04

Vol

22.47K

Mkt Cap

412.45M

Low

8.020

Amount

180.73K

EV/EBITDA(TTM)

11.41

Total Shares

50.16M

849.85M

EV/OCF(TTM)

13.66

P/S(TTM)

0.40

Enhabit, Inc. is a provider of home health and hospice services in the United States. Its segments include Home Health and Hospice. The Home Health segment provides a comprehensive range of Medicare-certified skilled home health services, including skilled nursing, physical, occupational and speech therapy, medical social work, and home health aide services. It works closely with patients, families, caregivers, and physicians to deliver data-driven, evidence-based care plans focused on patient needs and goals. Its home health services are provided by nurses, physical, occupational and speech therapists, medical social workers, and home health aides. The Hospice segment provides hospice services to terminally ill patients and their families. Hospice care focuses on the quality of life for patients experiencing an advanced, life- limiting illness by treating the symptoms of the disease, rather than the disease itself. It operates about 115 hospice agencies and 255 home health agencies.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q1

FY2025Q4

275.10M

+3.38%

0.115

-11.83%

269.40M

+3.66%

0.125

+25.15%

271.21M

+5.04%

0.157

+292.05%

Estimates Revision

The market is revising No Change the revenue expectations for Enhabit, Inc. (EHAB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 8.80%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+8.80%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast EHAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EHAB is 8.83 USD with a low forecast of 8.50 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

4 Hold

0 Sell

Hold

Current: 8.040

Low

8.50

Averages

8.83

High

9.00

Current: 8.040

Low

8.50

Averages

8.83

High

9.00

UBS

Neutral

downgrade

$10

2025-08-08

Reason

UBS

Price Target

$10

2025-08-08

downgrade

Neutral

Reason

UBS lowered the firm's price target on Enhabit to $8.50 from $10 and keeps a Neutral rating on the shares. Enhabit's Q2 results were largely positive, but the company is focused on combating the home health rate cut, the analyst tells investors in a research note.

Jefferies

Brian Tanquilut

Hold

Strong Buy

Upgrades

$8.25 → $9.5

2024-12-09

Reason

Jefferies

Brian Tanquilut

Price Target

$8.25 → $9.5

2024-12-09

Upgrades

Hold

Strong Buy

Reason

Jefferies upgraded Enhabit (EHAB) to Buy from Hold with a price target of $9.50, up from $8.25. The company's announcement of a new contract with UnitedHealth (UNH) that pays it a higher rate than its previous agreement eliminates an overhang and execution risk associated with potential revenue and EBITDA losses, the analyst tells investors in a research note. The firm believes the contract should enable Enhabit to focus more on driving growth rather than plugging the potential earnings hole that would have been caused by a UnitedHealth exit.

Leerink Partners

Whit Mayo

Hold

Reiterates

$8.5 → $8

2024-11-19

Reason

Leerink Partners

Whit Mayo

Price Target

$8.5 → $8

2024-11-19

Reiterates

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Enhabit Inc (EHAB.N) is 15.69, compared to its 5-year average forward P/E of 31.04. For a more detailed relative valuation and DCF analysis to assess Enhabit Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

31.04

Current PE

15.69

Overvalued PE

47.59

Undervalued PE

14.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

10.42

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

11.92

Undervalued EV/EBITDA

8.92

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.63

Current PS

8.15

Overvalued PS

1.63

Undervalued PS

-0.36